Liquidia Corporation Reports First Quarter 2026 Financial Results
Liquidia Corporation reported first quarter 2026 financial results highlighting approximately $130 million in net product sales of YUTREPIA®, sustained patient uptake, and net income of $53 million—marking its third consecutive profitable quarter. The company continues to advance clinical programs for its pulmonary hypertension treatments and expan…